LRRK2 and Parkinson disease: This is also true for PD-associated LRRK2-G2019S mutation carriers where activation of the LRRK2 kinase is modest whereas individuals with a VPS35 D620N mutation demonstrate much higher Rab10-Thr73 phosphorylation, reflecting its much greater catalytic effect on the LRRK2 kinase.